Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: Implications for treatment and surgical management

Juliet A. Emamaullee, Ryan Edgar, Christian Toso, Aducio Thiesen, Vincent Bain, David Bigam, Norman Kneteman, A. M. James Shapiro – 26 January 2010 – Epithelioid hemangioendothelioma (EHE) is a low‐grade, malignant vascular tumor that most commonly presents within the liver. Patients with hepatic EHE are often candidates for liver transplantation as the disease is usually multifocal at diagnosis.

Rapamycin inhibits cholangiocyte regeneration by blocking interleukin‐6–induced activation of signal transducer and activator of transcription 3 after liver transplantation

Li‐Ping Chen, Qi‐Hao Zhang, Geng Chen, Ye‐Yong Qian, Bing‐Yi Shi, Jia‐Hong Dong – 26 January 2010 – Cholangiocyte proliferation is necessary for biliary recovery from cold ischemia and reperfusion injury (CIRI), but there are few studies on its intracellular mechanism. In this process, the role of rapamycin, a new immunosuppressant used in liver transplantation, is still unknown.

Minimal but significant improvement in survival for non–hepatitis C–related adult liver transplant patients beyond the one‐year posttransplant mark

Geoffrey W. McCaughan, Nicholas A. Shackel, Simone I. Strasser, Pamela Dilworth, Patrick Tang – 26 January 2010 – Although 1‐year survival rates following liver transplantation over the last 20 years may have improved, there is doubt about improvement in long‐term survival. We examined survival with and without initial 12‐month mortality in adult liver transplant recipients over a 20‐year period. Patient and allograft survival for 3 different time periods was compared: 1986‐1994 (group 1, n = 547), 1995‐2000 (group 2, n = 735), and 2000‐2005 (group 3, n = 749).

Scoring short‐term mortality after liver transplantation

Chung‐Shun Wong, Wei‐Chen Lee, Chang‐Chyi Jenq, Ya‐Chung Tian, Ming‐Yang Chang, Chan‐Yu Lin, Ji‐Tseng Fang, Chih‐Wei Yang, Ming‐Hung Tsai, Hsin‐Chin Shih, Yung‐Chang Chen – 26 January 2010 – Liver transplantation can prolong survival and improve the quality of life of patients with end‐stage liver disease. This study retrospectively reviewed the medical records of 149 patients who had received liver transplants in a tertiary care university hospital from January 2000 to December 2007. Demographic, clinical, and laboratory variables were recorded.

T Cell‐mediated biliary epithelial‐to‐mesenchymal transition in liver allograft rejection

Karolina A. Rygiel, Helen Robertson, Joseph D. P. Willet, John G. Brain, Alastair D. Burt, David E. J. Jones, John A. Kirby – 25 January 2010 – Loss of bile duct epithelium is characteristic of early chronic rejection following liver transplantation. Recent studies have suggested that intrahepatic biliary epithelial cells can transform into myofibroblasts. This study examines the induction and molecular regulation of this transition during allograft rejection.

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B

Ting‐Tsung Chang, Ching‐Lung Lai, Seung Kew Yoon, Samuel S. Lee, Henrique Sergio M. Coelho, Flair Jose Carrilho, Fred Poordad, Waldemar Halota, Yves Horsmans, Naoky Tsai, Hui Zhang, Daniel J. Tenney, Ricardo Tamez, Uchenna Iloeje – 25 January 2010 – Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In study entecavir (ETV)‐022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for virologic suppression for hepatitis B e antigen (HBeAg)‐positive CHB. A total of 183 entecavir‐treated patients from ETV‐022 subsequently enrolled in study ETV‐901.

Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo

Inge Mannaerts, Nele R. Nuytten, Vera Rogiers, Karin Vanderkerken, Leo A. van Grunsven, Albert Geerts – 25 January 2010 – Hepatic stellate cell (HSC) activation is a pivotal step in the pathogenesis of liver fibrosis. The clarification of this transdifferentiation process is therefore important for the development of effective therapies for fibrosis. We analyzed the effect of a histone deacetylase inhibitor, valproic acid (VPA), on mouse HSC transdifferentiation in vitro and in vivo.

Subscribe to